Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1-Reference-Cited by-同舟云学术

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1

Published:2017-01-20 Issue:6 Volume:176 Page:929-938
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bar-Natan Michal¹,Stroopinsky Dina¹,Luptakova Katarina¹,Coll Maxwell D.¹,Apel Arie¹,Rajabi Hasan²,Pyzer Athalia R.¹,Palmer Kristen¹,Reagan Michaela R.³,Nahas Myrna R.¹,Karp Leaf Rebecca¹,Jain Salvia¹,Arnason Jon¹,Ghobrial Irene M.³,Anderson Kenneth C.²,Kufe Donald²,Rosenblatt Jacalyn¹,Avigan David¹

Affiliation:

1. Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA

2. Dana Farber Cancer Institute; Harvard Medical School; Boston MA USA

3. Jerome Lipper Multiple Myeloma Center; Department of Medical Oncology; Dana Farber Cancer Institute; Harvard Medical School; Boston MA USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14493/fullpdf

Reference49 articles.

1. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor;Ahmad;Cancer Research,2009

2. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop;Ahmad;Science Signalling,2011

3. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells;Alam;Oncotarget,2014

4. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma;Baldus;Histology and Histopathology,2007

5. Inhibition of MUC1-C suppresses MYC expression and attenuates malignant Growth in KRAS mutant lung adenocarcinomas;Bouillez;Cancer Research,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression;PLOS ONE;2023-12-01

2. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment;Frontiers in Oncology;2023-04-06

3. Anti-myeloma pro-apoptotic Pt(ii) diiodido complexes;Inorganic Chemistry Frontiers;2023

4. The multifaceted role of MUC1 in tumor therapy resistance;Clinical and Experimental Medicine;2022-12-23

5. Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells;Frontiers in Pharmacology;2022-09-09